Back
LYFE SCIENCES
Project: HERA
NM_000051.3:c.2413C>T
p.Arg805Ter  ·  ATM
Starting
Initialising…
0%
Legacy Engine
Ready
View Legacy →
Classification rationale
1

The ATM c.2413C>T (p.Arg805Ter; p.R805*) variant has been reported in ClinVar as Pathogenic by the ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel and is also cataloged in a cancer knowledgebase with variant-specific somatic context.

clinvar ↗ oncokb ↗
2

This variant is present in gnomAD v4.1 at an overall allele frequency of 0.00081% (13/1613688) with a highest observed East Asian frequency of 0.00669% (3/44820); these values are below the ATM BS1 and BA1 thresholds but the East Asian frequency is above the ATM PM2_Supporting threshold of 0.001%.

gnomad_v4 ↗ cspec ↗
3

Curated literature resources identify this variant in an ATM loss-of-function context, but no ATM-specific functional rescue data were confirmed here that meet the expert-panel requirements for PS3 or BS3.

oncokb ↗ PMID:27413114 ↗ PMID:30348496 ↗ PMID:30553448 ↗ cspec ↗
4

This variant introduces a premature termination codon at Arg805, well upstream of the ATM truncation cutoff used by the expert panel, which supports PVS1 and PM5_Supporting under the ATM-specific rules; REVEL was unavailable, BayesDel was 0.588046, and no SpliceAI-based evidence was captured for a splice-specific computational call.

cspec ↗ spliceai ↗
Applied criteria
Met
Not met
Not assessed
N/A
Very strong
Strong
Moderate
Supporting
Pathogenic evidence
PVS
PVS1
PS
PS1
PS2
PS3
PS4
PM
PM1
PM2
PM3
PM4
PM5
PM6
PP
PP1
PP2
PP3
PP4
PP5
Benign evidence
BA
BA1
BS
BS1
BS2
BS3
BS4
BP
BP1
BP2
BP3
BP4
BP5
BP6
BP7
PVS1
—
—
Rationale
Select a criterion to inspect its explanation.
Evidence used
  • —
Gaps remaining
  • —
Rule
—
Publications
—
Research and evidence
gnomAD v2.1 evidence
v2.1
gnomAD v4.1 evidence
v4.1
01
Population
gnomAD v2.1This variant is present in gnomAD v2.1 (AF= 3.98067e-05; MAF= 0.00398%, 10/251214 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.0003263; MAF= 0.03263%, 6/18388 alleles, homozygotes = 0); grpmax FAF= 0.00014149.
gnomAD v4.1This variant is present in gnomAD v4.1 (AF= 8.05608e-06; MAF= 0.00081%, 13/1613688 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 6.69344e-05; MAF= 0.00669%, 3/44820 alleles, homozygotes = 0); grpmax FAF= 1.775e-05.
gnomAD v2 ↗ gnomAD v4 ↗
ClinVar evidence
02
ClinVar
This variant has been reported in ClinVar as Pathogenic (17 clinical laboratories) and as Pathogenic by ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen (expert panel). (ClinVarID = 216021)
ClinVar ↗
Functional evidence
03
Functional
OncoKB: Likely Oncogenic
OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.
OncoKB ↗
In silico evidence
04
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.18). BayesDel score = 0.588046.
SpliceAI ↗
COSMIC evidence
05
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV53736642, n = 11 times).
COSMIC ↗
Cancer hotspots evidence
06
Cancer hotspots Not found
This variant does not lie in a statistically significant hotspot.
ResidueR805
Hotspots ↗